Carole Ho, M.D.

Carole Ho, M.D.

Chief Medical Officer and Head of Development (until November 14, 2025)atDenali Therapeutics· In proxies 2021–2025

Pay in FY2025-5% from the year before · Denali Therapeutics stock -19.0% the same year

Carole Ho, M.D. was paid $3.8M in FY2025 (Dec), down 5%. Denali Therapeutics stock fell 19.0% that year.

Pay$100 in the stock at the end of FY20 → $20
Pay is from the Summary Compensation Table of each Denali Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Denali TherapeuticsPublic company · 5 yr
    • Chief Medical Officer and Head of Development (until November 14, 2025)2021 – Present · 5 yrStock in role -78%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?